verapamil has been researched along with Degenerative Diseases, Central Nervous System in 4 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
Excerpt | Relevance | Reference |
---|---|---|
" The CCBs nimodipine (NDP) and verapamil (VPM) both significantly suppressed toxic secretions from human astrocytes and astrocytoma U-373 MG cells that were induced by interferon (IFN)-γ." | 1.38 | Inhibition of human astrocyte and microglia neurotoxicity by calcium channel blockers. ( Hashioka, S; Klegeris, A; McGeer, PL, 2012) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (50.00) | 29.6817 |
2010's | 2 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bartels, AL | 1 |
de Klerk, OL | 1 |
Kortekaas, R | 1 |
de Vries, JJ | 1 |
Leenders, KL | 1 |
Hashioka, S | 1 |
Klegeris, A | 1 |
McGeer, PL | 1 |
Sarang, SS | 1 |
Yoshida, T | 1 |
Cadet, R | 1 |
Valeras, AS | 1 |
Jensen, RV | 1 |
Gullans, SR | 1 |
Doyle, KM | 1 |
Kirby, BP | 1 |
Murphy, D | 1 |
Shaw, GG | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Randomized Double Blind Placebo Controlled Trial of Verapamil in Chronic Rhinosinusitis[NCT02454608] | 29 participants (Actual) | Interventional | 2015-05-31 | Terminated (stopped due to Evidence that the dose is insufficient.) | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
(NCT02454608)
Timeframe: Mean change between baseline and week 8 measurements
Intervention | mmHg (Mean) |
---|---|
Treatment | -0.6 |
Control | 1 |
(NCT02454608)
Timeframe: Mean change between baseline and week 8 measurements.
Intervention | beats per minute (Mean) |
---|---|
Treatment | -1.4 |
Control | 4 |
Minimum Score: 0 Maximum Score: 12 Higher value represents worse outcome. (NCT02454608)
Timeframe: baseline to week 8
Intervention | units on a scale (Least Squares Mean) |
---|---|
Treatment | -1.3 |
Control | -0.25 |
Minimum Score: 0 Maximum Score: 24 Higher value represents worse outcome. (NCT02454608)
Timeframe: Week 8
Intervention | units on a scale (Mean) |
---|---|
Treatment | 12.5 |
Control | 17.7 |
Minimum Score: 0 Maximum Score: 100 A higher score indicates a worse outcome. (NCT02454608)
Timeframe: baseline to week 8
Intervention | units on a scale (Least Squares Mean) |
---|---|
Treatment | -44.03 |
Control | -6.07 |
Minimum Score: 0 Maximum Score: 110 A higher score indicates a worse outcome (NCT02454608)
Timeframe: baseline to week 8
Intervention | units on a scale (Least Squares Mean) |
---|---|
Treatment | -27.3 |
Control | 0.4 |
(NCT02454608)
Timeframe: Mean change between baseline and week 8 measurements
Intervention | mmHg (Mean) |
---|---|
Treatment | -4.5 |
Control | -6.6 |
Minimum Score: 0 Maximum Score: 100 A higher score indicates a worse outcome. (NCT02454608)
Timeframe: baseline to week 56
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Medicine Completers, baseline | Medicine Completers, week 56 | Surgical Completers, baseline | Surgical Completers, week 12 | |
Open Label | 64.3 | 35.0 | 90.0 | 16.7 |
Minimum Score: 0 Maximum Score: 110 A higher score indicates a worse outcome (NCT02454608)
Timeframe: baseline to week 56
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Medicine Completers, baseline | Medicine Completers, week 56 | Surgical Completers, baseline | Surgical Completers, week 12 | |
Open Label | 31.8 | 24.14 | 72.00 | 8.00 |
1 review available for verapamil and Degenerative Diseases, Central Nervous System
Article | Year |
---|---|
11C-verapamil to assess P-gp function in human brain during aging, depression and neurodegenerative disease.
Topics: Aging; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Brain Diseases; | 2010 |
3 other studies available for verapamil and Degenerative Diseases, Central Nervous System
Article | Year |
---|---|
Inhibition of human astrocyte and microglia neurotoxicity by calcium channel blockers.
Topics: Astrocytes; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Cells, Cultured; Chemokin | 2012 |
Discovery of molecular mechanisms of neuroprotection using cell-based bioassays and oligonucleotide arrays.
Topics: Biological Assay; Drug Evaluation, Preclinical; Gene Expression Profiling; Gene Expression Regulatio | 2002 |
Effect of L-type calcium channel antagonists on spermine-induced CNS excitation in vivo.
Topics: Amines; Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Central Nervous System; Convuls | 2005 |